Table 1.

Characteristics of included studies.

Author	Year	Site	Age (Mean ± SD)	Number	Severity	Causes of hair loss	Duration	Frequence (daily)	Dose	Change in length or density		Mode of assessment	Side effects (n)
Gurpreet S. Ahluwalia et al.	2013	eyelash	NA	Bimatoprost:96 Placebo:34	severe	chemotherapy	12 m	1	0.05 mL	Placebo:35.6	digital image analysis	Bimatoprost:12 Placebo:0	Bimatoprost:39.1
A. Rossi et al.	2017	scalp	20–65	Cetirizine:67 Placebo:18	NA	androgenetic alopecia	6 m	NA	1 mL	Placebo:2.59 ± 0.55	global photographic	NA	Cetirizine:30.31 ± 4.21
Ulrike Blume-Peytavi et al.	2012	scalp	23 to 35	Latanoprost:16 Placebo:16	mild	androgenetic alopecia	24 w	1	0.05 mL	Placebo:0.10	global photographic	Latanoprost:6 Placebo:1	Latanoprost:0.22
Mohammadreza Rafati et al.	2022	scalp	Latanoprost:29.2 ± 9.8 Placebo:29.8 ± 12.1	Latanoprost:12 Placebo:12	NA	alopecia areata	12 w	1	0.25 mL	Placebo:14.6 ± 18.6	global photographic	the same between groups	Latanoprost:37.2 ± 26.1
Mark Borchert et al.	2016	eyelash	Bimatoprost:14.5 Placebo:14.6	Bimatoprost:48 Placebo:23	GEA < 3	multiple factors	4 m	1	0.05 mL	Placebo:0.79	digital image analysis	Bimatoprost:12 Placebo:0	Bimatoprost:1.21
Jean Carruthers et al.	2016	eyebrow	Bimatoprost BID:53.5 ± 10.82 Bimatoprost QD:55.0 ± 11.11 Placebo:53.5 ± 9.8	Bimatoprost BID:118 Bimatoprost QD:118 Placebo:121	GEBA≤2	NA	7 m	1 or 2	0.05 mL	Placebo:6.42	digital image analysis	Bimatoprost BID:42 Bimatoprost QD:48 Placebo:41	Bimatoprost:

GEA, Global Eyelash Assessment; GEBA, Global Eyebrow Assessment; QD, Bimatoprost once daily; BID, Bimatoprost twice daily.